Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cloud Computing | 5 | 2024 | 11 | 2.910 |
Why?
|
Genomics | 12 | 2021 | 720 | 2.450 |
Why?
|
Software | 10 | 2023 | 654 | 2.280 |
Why?
|
Neoplasms | 16 | 2023 | 2898 | 1.740 |
Why?
|
Biomedical Research | 6 | 2022 | 376 | 1.680 |
Why?
|
Genome, Human | 8 | 2021 | 756 | 1.650 |
Why?
|
Information Dissemination | 6 | 2021 | 103 | 1.630 |
Why?
|
Electronic Health Records | 3 | 2024 | 319 | 1.560 |
Why?
|
Databases, Factual | 6 | 2020 | 814 | 1.120 |
Why?
|
Datasets as Topic | 3 | 2017 | 71 | 1.080 |
Why?
|
Veterans | 2 | 2024 | 72 | 1.070 |
Why?
|
Databases, Genetic | 3 | 2021 | 260 | 1.020 |
Why?
|
Vocabulary, Controlled | 1 | 2023 | 13 | 0.910 |
Why?
|
Genome, Bacterial | 3 | 2022 | 139 | 0.910 |
Why?
|
Computational Biology | 6 | 2019 | 528 | 0.900 |
Why?
|
Data Accuracy | 2 | 2022 | 31 | 0.880 |
Why?
|
Medical Informatics | 2 | 2024 | 47 | 0.870 |
Why?
|
Whole Genome Sequencing | 2 | 2022 | 76 | 0.860 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2022 | 12 | 0.850 |
Why?
|
Antitubercular Agents | 1 | 2022 | 52 | 0.830 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2022 | 44 | 0.820 |
Why?
|
Medical Oncology | 4 | 2024 | 359 | 0.810 |
Why?
|
Precision Medicine | 9 | 2024 | 395 | 0.800 |
Why?
|
Drosophila melanogaster | 6 | 2014 | 599 | 0.740 |
Why?
|
Mycobacterium tuberculosis | 1 | 2022 | 186 | 0.710 |
Why?
|
Disease | 2 | 2017 | 90 | 0.690 |
Why?
|
DNA Mutational Analysis | 2 | 2021 | 526 | 0.690 |
Why?
|
Gene Regulatory Networks | 3 | 2010 | 296 | 0.660 |
Why?
|
Mutation | 6 | 2024 | 3968 | 0.660 |
Why?
|
Spatial Analysis | 1 | 2017 | 7 | 0.620 |
Why?
|
Information Storage and Retrieval | 4 | 2023 | 120 | 0.620 |
Why?
|
Data Collection | 1 | 2018 | 372 | 0.590 |
Why?
|
Neuroblastoma | 2 | 2019 | 374 | 0.590 |
Why?
|
Algorithms | 5 | 2018 | 1830 | 0.570 |
Why?
|
Genome-Wide Association Study | 4 | 2020 | 1621 | 0.560 |
Why?
|
Humans | 50 | 2024 | 86643 | 0.550 |
Why?
|
Computer Systems | 1 | 2014 | 79 | 0.480 |
Why?
|
Evolution, Molecular | 1 | 2020 | 813 | 0.480 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 827 | 0.460 |
Why?
|
United States | 12 | 2023 | 6672 | 0.440 |
Why?
|
Data Mining | 2 | 2014 | 42 | 0.440 |
Why?
|
Liquid Biopsy | 3 | 2023 | 33 | 0.430 |
Why?
|
Gene Expression Regulation | 5 | 2021 | 1920 | 0.430 |
Why?
|
Prostatic Neoplasms | 1 | 2024 | 1721 | 0.430 |
Why?
|
DNA Methylation | 4 | 2021 | 628 | 0.430 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2021 | 70 | 0.420 |
Why?
|
Systems Biology | 1 | 2012 | 42 | 0.410 |
Why?
|
Databases, Nucleic Acid | 1 | 2011 | 41 | 0.390 |
Why?
|
Molecular Sequence Annotation | 3 | 2021 | 67 | 0.390 |
Why?
|
Transcription Factors | 7 | 2014 | 1565 | 0.380 |
Why?
|
Phenotype | 5 | 2022 | 2378 | 0.380 |
Why?
|
Models, Statistical | 2 | 2018 | 574 | 0.350 |
Why?
|
User-Computer Interface | 3 | 2021 | 185 | 0.340 |
Why?
|
Models, Molecular | 2 | 2004 | 1286 | 0.340 |
Why?
|
Base Sequence | 5 | 2021 | 2330 | 0.330 |
Why?
|
Reproducibility of Results | 6 | 2023 | 2705 | 0.320 |
Why?
|
Genome, Insect | 3 | 2014 | 75 | 0.310 |
Why?
|
Biomarkers, Tumor | 3 | 2021 | 1464 | 0.300 |
Why?
|
Computer Security | 3 | 2019 | 16 | 0.290 |
Why?
|
Sequence Analysis, DNA | 3 | 2018 | 853 | 0.290 |
Why?
|
Computer Graphics | 1 | 2006 | 100 | 0.290 |
Why?
|
Multiple Sclerosis | 4 | 2002 | 262 | 0.280 |
Why?
|
Genome | 1 | 2009 | 372 | 0.280 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 297 | 0.260 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 2271 | 0.250 |
Why?
|
Computer Communication Networks | 2 | 2016 | 23 | 0.250 |
Why?
|
Chemistry | 1 | 2004 | 54 | 0.250 |
Why?
|
Organic Chemicals | 1 | 2004 | 33 | 0.240 |
Why?
|
Multivariate Analysis | 1 | 2006 | 999 | 0.240 |
Why?
|
Regulatory Sequences, Nucleic Acid | 3 | 2014 | 148 | 0.230 |
Why?
|
Halomonadaceae | 2 | 2013 | 4 | 0.230 |
Why?
|
Chromatin | 5 | 2014 | 380 | 0.230 |
Why?
|
Internet | 3 | 2017 | 312 | 0.220 |
Why?
|
Circulating Tumor DNA | 1 | 2023 | 37 | 0.220 |
Why?
|
Terminology as Topic | 1 | 2004 | 217 | 0.220 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2003 | 122 | 0.210 |
Why?
|
Models, Biological | 1 | 2009 | 1749 | 0.210 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2011 | 133 | 0.210 |
Why?
|
Microbial Sensitivity Tests | 1 | 2022 | 143 | 0.200 |
Why?
|
Pharmaceutical Preparations | 1 | 2003 | 92 | 0.200 |
Why?
|
5-Methylcytosine | 2 | 2019 | 112 | 0.190 |
Why?
|
Specimen Handling | 1 | 2021 | 98 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 6 | 2002 | 3362 | 0.190 |
Why?
|
Viruses | 1 | 2021 | 78 | 0.190 |
Why?
|
Chromothripsis | 1 | 2020 | 5 | 0.190 |
Why?
|
Health Status Disparities | 1 | 2022 | 170 | 0.180 |
Why?
|
Academic Success | 1 | 2020 | 11 | 0.180 |
Why?
|
Promoter Regions, Genetic | 3 | 2020 | 937 | 0.180 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 171 | 0.180 |
Why?
|
Oncogenes | 1 | 2020 | 88 | 0.180 |
Why?
|
Veterans Health | 1 | 2019 | 15 | 0.180 |
Why?
|
Telomerase | 1 | 2020 | 55 | 0.180 |
Why?
|
Mutagenesis | 1 | 2020 | 199 | 0.180 |
Why?
|
Cellular Senescence | 1 | 2020 | 94 | 0.180 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 329 | 0.170 |
Why?
|
Ecosystem | 2 | 2023 | 316 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2024 | 2262 | 0.170 |
Why?
|
Telomere | 1 | 2020 | 108 | 0.170 |
Why?
|
Epigenomics | 1 | 2019 | 100 | 0.170 |
Why?
|
Prognosis | 3 | 2022 | 3679 | 0.170 |
Why?
|
Schools, Medical | 1 | 2020 | 123 | 0.170 |
Why?
|
RNA Splicing | 1 | 2020 | 142 | 0.170 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 394 | 0.170 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2019 | 71 | 0.170 |
Why?
|
Access to Information | 1 | 2018 | 27 | 0.160 |
Why?
|
Meta-Analysis as Topic | 1 | 2018 | 87 | 0.160 |
Why?
|
Male | 8 | 2024 | 40965 | 0.160 |
Why?
|
Mexican Americans | 1 | 2017 | 63 | 0.160 |
Why?
|
Quantitative Trait Loci | 2 | 2018 | 576 | 0.150 |
Why?
|
Cohort Studies | 2 | 2022 | 2767 | 0.150 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 329 | 0.150 |
Why?
|
Models, Genetic | 2 | 2013 | 926 | 0.150 |
Why?
|
Research | 1 | 2018 | 253 | 0.150 |
Why?
|
Pharmacogenomic Testing | 1 | 2017 | 97 | 0.150 |
Why?
|
Brain | 4 | 2002 | 2216 | 0.140 |
Why?
|
Computing Methodologies | 1 | 2016 | 9 | 0.140 |
Why?
|
Phylogeny | 1 | 2022 | 1137 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 456 | 0.140 |
Why?
|
Hemiptera | 2 | 2013 | 7 | 0.140 |
Why?
|
Pandemics | 1 | 2022 | 740 | 0.140 |
Why?
|
MicroRNAs | 1 | 2021 | 534 | 0.140 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 265 | 0.140 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2021 | 1204 | 0.130 |
Why?
|
Symbiosis | 2 | 2013 | 118 | 0.130 |
Why?
|
DNA, Bacterial | 2 | 2013 | 236 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1075 | 0.130 |
Why?
|
Students, Medical | 1 | 2020 | 384 | 0.130 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2017 | 137 | 0.130 |
Why?
|
Chromatin Assembly and Disassembly | 2 | 2011 | 69 | 0.120 |
Why?
|
Genetic Variation | 2 | 2018 | 1351 | 0.120 |
Why?
|
Erythroid Cells | 1 | 2013 | 14 | 0.120 |
Why?
|
Gene Expression | 1 | 2018 | 1284 | 0.120 |
Why?
|
Systems Integration | 1 | 2014 | 35 | 0.120 |
Why?
|
Cell Proliferation | 1 | 2020 | 1578 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2013 | 52 | 0.120 |
Why?
|
Female | 9 | 2020 | 44532 | 0.120 |
Why?
|
Binding Sites | 3 | 2014 | 1098 | 0.120 |
Why?
|
Metagenomics | 1 | 2014 | 83 | 0.110 |
Why?
|
Retrospective Studies | 2 | 2024 | 8489 | 0.110 |
Why?
|
Incidence | 1 | 2017 | 1577 | 0.110 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2012 | 79 | 0.110 |
Why?
|
Models, Chemical | 2 | 2004 | 178 | 0.110 |
Why?
|
Biotechnology | 1 | 2012 | 28 | 0.110 |
Why?
|
Transcription, Genetic | 2 | 2014 | 1135 | 0.110 |
Why?
|
Chromosome Deletion | 1 | 2012 | 229 | 0.100 |
Why?
|
Child | 5 | 2019 | 6927 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 1197 | 0.100 |
Why?
|
Gene Components | 1 | 2011 | 6 | 0.100 |
Why?
|
Leukemia, Myeloid | 1 | 2012 | 249 | 0.100 |
Why?
|
Quality Control | 1 | 2011 | 117 | 0.100 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 1384 | 0.100 |
Why?
|
Forecasting | 1 | 2012 | 304 | 0.100 |
Why?
|
Conserved Sequence | 1 | 2011 | 210 | 0.090 |
Why?
|
Research Design | 1 | 2014 | 594 | 0.090 |
Why?
|
RNA, Messenger | 2 | 2017 | 1981 | 0.090 |
Why?
|
Machine Learning | 2 | 2024 | 232 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2012 | 403 | 0.090 |
Why?
|
Radiology | 1 | 2012 | 194 | 0.090 |
Why?
|
Animals | 9 | 2014 | 26582 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2011 | 246 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2012 | 536 | 0.080 |
Why?
|
Computer Simulation | 2 | 2018 | 1078 | 0.080 |
Why?
|
Drosophila Proteins | 2 | 2010 | 488 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2012 | 696 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 1373 | 0.080 |
Why?
|
Aged | 3 | 2022 | 18415 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 469 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2018 | 2903 | 0.070 |
Why?
|
Spinal Cord | 2 | 1998 | 249 | 0.070 |
Why?
|
Spinal Canal | 1 | 1986 | 4 | 0.070 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 2360 | 0.070 |
Why?
|
Treatment Outcome | 1 | 2018 | 7993 | 0.070 |
Why?
|
Facial Injuries | 1 | 1985 | 19 | 0.070 |
Why?
|
Pattern Recognition, Automated | 1 | 2006 | 217 | 0.070 |
Why?
|
Craniocerebral Trauma | 1 | 1985 | 52 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 1208 | 0.060 |
Why?
|
Xenobiotics | 1 | 2003 | 7 | 0.060 |
Why?
|
Genotype | 2 | 2018 | 1851 | 0.060 |
Why?
|
Database Management Systems | 1 | 2003 | 41 | 0.060 |
Why?
|
Infant, Newborn | 4 | 2019 | 2379 | 0.050 |
Why?
|
Enhancer Elements, Genetic | 2 | 2014 | 266 | 0.050 |
Why?
|
Public-Private Sector Partnerships | 1 | 2020 | 5 | 0.050 |
Why?
|
Histones | 2 | 2013 | 311 | 0.050 |
Why?
|
College Admission Test | 1 | 2020 | 2 | 0.050 |
Why?
|
New York City | 1 | 2020 | 59 | 0.050 |
Why?
|
School Admission Criteria | 1 | 2020 | 23 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2019 | 26 | 0.040 |
Why?
|
Protein Binding | 2 | 2014 | 1456 | 0.040 |
Why?
|
Infant | 3 | 2019 | 3046 | 0.040 |
Why?
|
Blood Platelets | 1 | 2019 | 149 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2023 | 426 | 0.040 |
Why?
|
Child, Preschool | 3 | 2019 | 3612 | 0.040 |
Why?
|
Mass Screening | 1 | 2022 | 618 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 3030 | 0.040 |
Why?
|
Family Health | 1 | 2017 | 162 | 0.040 |
Why?
|
Lung | 1 | 2023 | 1170 | 0.040 |
Why?
|
3' Untranslated Regions | 1 | 2017 | 92 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2017 | 106 | 0.040 |
Why?
|
Pilot Projects | 1 | 2019 | 839 | 0.040 |
Why?
|
Carcinogenesis | 1 | 2018 | 195 | 0.040 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2016 | 6 | 0.040 |
Why?
|
Medical Records Systems, Computerized | 1 | 2016 | 40 | 0.030 |
Why?
|
Government Regulation | 1 | 2016 | 49 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2017 | 270 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2021 | 1939 | 0.030 |
Why?
|
Logistic Models | 1 | 2020 | 1186 | 0.030 |
Why?
|
Confidentiality | 1 | 2016 | 78 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 144 | 0.030 |
Why?
|
Gene Frequency | 1 | 2017 | 677 | 0.030 |
Why?
|
Pedigree | 1 | 2017 | 966 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2017 | 201 | 0.030 |
Why?
|
Fibroblasts | 1 | 2018 | 729 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 1056 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 217 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2018 | 418 | 0.030 |
Why?
|
Pharmacogenetics | 1 | 2019 | 434 | 0.030 |
Why?
|
Nucleotide Motifs | 1 | 2014 | 47 | 0.030 |
Why?
|
Hematoma | 2 | 1985 | 104 | 0.030 |
Why?
|
Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
Penetrance | 1 | 2013 | 44 | 0.030 |
Why?
|
Risk Assessment | 1 | 2021 | 2261 | 0.030 |
Why?
|
Dioxygenases | 1 | 2013 | 74 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2013 | 158 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
Inpatients | 1 | 1996 | 297 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2012 | 12 | 0.030 |
Why?
|
U937 Cells | 1 | 2012 | 32 | 0.030 |
Why?
|
K562 Cells | 1 | 2012 | 43 | 0.030 |
Why?
|
Cytosine | 1 | 2013 | 127 | 0.030 |
Why?
|
Publishing | 1 | 2014 | 90 | 0.030 |
Why?
|
Adolescent | 3 | 2019 | 8981 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2012 | 187 | 0.030 |
Why?
|
Adult | 4 | 2019 | 25648 | 0.030 |
Why?
|
Haploinsufficiency | 1 | 2012 | 62 | 0.030 |
Why?
|
Mice, SCID | 1 | 2012 | 252 | 0.030 |
Why?
|
Risk Factors | 1 | 2022 | 5417 | 0.030 |
Why?
|
Cerebral Hemorrhage | 2 | 1985 | 325 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2012 | 265 | 0.030 |
Why?
|
HeLa Cells | 1 | 2012 | 498 | 0.030 |
Why?
|
RNA Interference | 1 | 2012 | 369 | 0.030 |
Why?
|
Silencer Elements, Transcriptional | 1 | 2011 | 5 | 0.030 |
Why?
|
Insulator Elements | 1 | 2011 | 7 | 0.030 |
Why?
|
Histone Code | 1 | 2011 | 19 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2012 | 458 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 782 | 0.020 |
Why?
|
RNA, Small Untranslated | 1 | 2010 | 14 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 279 | 0.020 |
Why?
|
Acute Disease | 1 | 2012 | 826 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2011 | 63 | 0.020 |
Why?
|
Nucleosomes | 1 | 2010 | 54 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 879 | 0.020 |
Why?
|
Genes, Insect | 1 | 2010 | 183 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2013 | 2818 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2012 | 1924 | 0.020 |
Why?
|
Young Adult | 1 | 2019 | 5976 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 2426 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2010 | 479 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 1991 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2017 | 6509 | 0.020 |
Why?
|
Spinal Cord Diseases | 1 | 1986 | 29 | 0.020 |
Why?
|
Birth Injuries | 1 | 1985 | 4 | 0.020 |
Why?
|
Skull Fractures | 1 | 1985 | 24 | 0.020 |
Why?
|
Orbital Fractures | 1 | 1985 | 13 | 0.020 |
Why?
|
Mastoid | 1 | 1985 | 17 | 0.020 |
Why?
|
Brain Edema | 1 | 1985 | 50 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 2357 | 0.020 |
Why?
|
Brain Concussion | 1 | 1985 | 59 | 0.020 |
Why?
|
Subarachnoid Hemorrhage | 1 | 1985 | 137 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1985 | 318 | 0.010 |
Why?
|
Practice Guidelines as Topic | 2 | 1998 | 1036 | 0.010 |
Why?
|
Middle Aged | 2 | 2017 | 25028 | 0.010 |
Why?
|
Mice | 1 | 2012 | 11352 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 1985 | 2601 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 1998 | 172 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 1998 | 268 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 1998 | 220 | 0.010 |
Why?
|
Patient Care Planning | 1 | 1996 | 81 | 0.010 |
Why?
|
Evoked Potentials | 1 | 1977 | 190 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1996 | 143 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1977 | 212 | 0.010 |
Why?
|
Brain Diseases | 1 | 1996 | 180 | 0.010 |
Why?
|
Cognition | 1 | 1998 | 570 | 0.010 |
Why?
|
Contrast Media | 1 | 1998 | 1078 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 1977 | 584 | 0.010 |
Why?
|
Biomarkers | 1 | 1998 | 1718 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 1996 | 763 | 0.010 |
Why?
|
Haplorhini | 1 | 1977 | 81 | 0.000 |
Why?
|
Hypotension | 1 | 1977 | 70 | 0.000 |
Why?
|
Electric Stimulation | 1 | 1977 | 347 | 0.000 |
Why?
|
Hypertension | 1 | 1977 | 1141 | 0.000 |
Why?
|